Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
investigational drug
nonsteroidal antiandrogen |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1398044-42-7
|
| gptkbp:chemicalFormula |
C25H19F3N4O
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2023)
|
| gptkbp:countryOfOrigin |
gptkb:China
|
| gptkbp:developedBy |
Kintor Pharmaceutical
|
| gptkbp:hasSMILES |
C1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C(=O)NC4=CC=C(C=C4)C(F)(F)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
Proxalutamide
|
| gptkbp:intendedUse |
treatment of breast cancer
treatment of prostate cancer potential COVID-19 therapy |
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
androgen receptor antagonist
|
| gptkbp:molecularWeight |
448.44 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL4297596
71587661 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
GT-0918
GT0918 |
| gptkbp:UNII |
6Q1K1Y1A2E
|
| gptkbp:bfsParent |
gptkb:Kintor_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|